Table 3.
Clinical trials exploring anti BRAF-EGFR combinations in mCRC.
| Trial | Phase | Treatment | N° patients | ORR (%) | mPFS months | mOS months |
|---|---|---|---|---|---|---|
| Kopetz 2014 | II | Vemurafenib | 21 | 5% | 2.1 | 7.7 |
| Hyman 2015 | II | Vemurafenib | 10 | 0 | 4.5 | 9.3 |
| Gomez-Roca 2014 | I | Encorafenib | 18 | 0 | 4 | - |
| Hyman 2015 | II | Vemurafenib + cetuximab | 27 | 3.7 | 3.7 | 7.1 |
| Yaeger 2015 | II | Vemurafenib + panitumumab | 15 | 13 | 3.2 | 7.6 |
| Corcoran 2015 | II | Dabrafenib + trametinib | 43 | 12 | 3.5 | - |
| Corcoran 2016 | II | Dabrafenib + trametinib +/- panitumumab versus trametinib + panitumumab |
20 91 31 |
10 21 0 |
3.5 4.2 2.6 |
- 9.1 |
| Tabernero 2016 | II | Encorafenib+ cetuximab +/- alpelisib | 50 (doublet) 52 (triplet) |
22 27 |
4.2 5.4 |
- 15.2 |
| SWOG 1406
Kopetz 2017 |
II | Vemurafenib+ cetuximab+ irinotecan | 106 | 16 | 4.4 | - |
| BEACON
Kopetz 2019 |
III | Encorafenib + cetuximab +/-binimetinib versus
irinotecan +cetuximab |
224 (triplet) 220 (doublet) 221 (control) |
26 (update 27) 26 (update 20) 2 (update 2) |
4.3 4.2 1.5 |
9 (update 9.3) 8.4 (update 9.3) 5.4 (update 5.9) |
| ANCHOR
(Ongoing) |
III | First line: encorafenib + cetuximab +/- binimetinib versus
irinotecan +cetuximab |
- | - | - | - |
EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; mPFS, median progression free survival; mOS, median overall survival; ORR, overall response rate.